{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T23:41:02Z","timestamp":1783122062660,"version":"3.54.6"},"reference-count":45,"publisher":"The Journal of Rheumatology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2014,4]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To evaluate the humoral immune response to pneumococcal and influenza vaccination in adults with rheumatoid arthritis (RA) receiving certolizumab pegol (CZP).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>In this 6-week, single-blind, placebo-controlled trial with optional 6-month open-label extension (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00993668\">NCT00993668<\/jats:ext-link>), patients were stratified by concomitant methotrexate (MTX) use and randomized to receive CZP 400 mg (loading dose; according to CZP label) or placebo at weeks 0, 2, and 4. Pneumococcal (polysaccharide 23) and influenza vaccines were administered at Week 2. Satisfactory humoral immune response, defined as \u2265 2-fold titer increase in \u2265 3 of 6 pneumococcal antigens and \u2265 4-fold titer increase in \u2265 2 of 3 influenza antigens, were assessed independently 4 weeks after vaccination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Following pneumococcal vaccination, 62.5% of placebo patients and 54.5% of CZP patients without effective titers at baseline achieved a humoral response (difference in proportions was \u22128.0 percentage points; 95% CI \u221222.5 to 6.6%). Following influenza vaccination, 61.4% of placebo and 53.5% of CZP patients without effective titers at baseline achieved a humoral response (difference in proportions: \u22128.0 percentage points; 95% CI \u221222.9 to 7.0%). In all patients, including those with effective titers at baseline, 58.2% of placebo and 53.3% of CZP patients developed satisfactory pneumococcal titers, and 54.1% of placebo and 50.5% of CZP patients developed satisfactory influenza antibody titers. Vaccine responses to pneumococcal and influenza antigens were reduced similarly in both treatment groups with concomitant MTX use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Humoral immune responses to pneumococcal and influenza vaccination are not impaired when given during the loading phase of CZP treatment in patients with RA. (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"ClinicalTrials.gov\" xlink:type=\"simple\">ClinicalTrials.gov<\/jats:ext-link><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00993668\">NCT00993668<\/jats:ext-link>).<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.130945","type":"journal-article","created":{"date-parts":[[2014,3,2]],"date-time":"2014-03-02T01:34:26Z","timestamp":1393724066000},"page":"648-657","source":"Crossref","is-referenced-by-count":71,"title":["Vaccine Responses in Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol: Results from a Single-blind Randomized Phase IV Trial"],"prefix":"10.3899","volume":"41","author":[{"given":"Alan J.","family":"Kivitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Schechtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Texter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Fichtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"de Longueville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot K.","family":"Chartash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2014,3,1]]},"reference":[{"key":"2018112909324022000_41.4.648.1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780140119"},{"key":"2018112909324022000_41.4.648.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10524"},{"key":"2018112909324022000_41.4.648.3","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100995"},{"key":"2018112909324022000_41.4.648.4","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90131-7"},{"key":"2018112909324022000_41.4.648.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(05)70327-6"},{"key":"2018112909324022000_41.4.648.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.04.010"},{"key":"2018112909324022000_41.4.648.7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq249a"},{"key":"2018112909324022000_41.4.648.8","first-page":"1","article-title":"General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"60","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2018112909324022000_41.4.648.9","unstructured":"Janssen Biotech Inc . Remicade prescribing information. Revised October 2011. [Internet. Accessed January 27, 2014.] Available from: www.remicade.com\/shared\/product\/remicade\/prescribing-information.pdf"},{"key":"2018112909324022000_41.4.648.10","unstructured":"Abbott Laboratories . Humira prescribing information. Revised February 2013. [Internet. Accessed January 27, 2014.] Available from: http:\/\/www.rxabbvie.com\/pdf\/humira.pdf"},{"key":"2018112909324022000_41.4.648.11","unstructured":"UCB Pharma . Cimzia prescribing information. Revised November 2012. [Internet. Accessed January 27, 2014.] Available from: www.cimzia.com\/pdf\/MedicationGuide.pdf"},{"key":"2018112909324022000_41.4.648.12","unstructured":"Janssen Biotech Inc . Simponi (Golimumab) prescribing information. Revised May 2013. [Internet. Accessed January 27, 2014.] Available from: https:\/\/www.simponi.com\/prescribing-information.pdf"},{"key":"2018112909324022000_41.4.648.13","unstructured":"Amgen Inc., Pfizer Inc . Enbrel (etanercept) prescribing information. Revised December 2012. [Internet. Accessed January 27, 2014.] Available from: http:\/\/pi.amgen.com\/united_states\/enbrel\/derm\/enbrel_pi.pdf"},{"key":"2018112909324022000_41.4.648.14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq297"},{"key":"2018112909324022000_41.4.648.15","doi-asserted-by":"publisher","DOI":"10.1086\/587063"},{"key":"2018112909324022000_41.4.648.16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq183"},{"key":"2018112909324022000_41.4.648.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.077552"},{"key":"2018112909324022000_41.4.648.18","first-page":"272","article-title":"Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab","volume":"34","author":"Kaine","year":"2007","journal-title":"J Rheumatol"},{"key":"2018112909324022000_41.4.648.19","doi-asserted-by":"publisher","DOI":"10.1053\/j.semarthrit.2003.10.003"},{"key":"2018112909324022000_41.4.648.20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei193"},{"key":"2018112909324022000_41.4.648.21","first-page":"952","article-title":"Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone","volume":"34","author":"Visvanathan","year":"2007","journal-title":"J Rheumatol"},{"key":"2018112909324022000_41.4.648.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.25034"},{"key":"2018112909324022000_41.4.648.23","doi-asserted-by":"publisher","DOI":"10.1186\/ar2174"},{"key":"2018112909324022000_41.4.648.24","doi-asserted-by":"publisher","DOI":"10.1002\/art.25033"},{"key":"2018112909324022000_41.4.648.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2009.10.008"},{"key":"2018112909324022000_41.4.648.26","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.099291"},{"key":"2018112909324022000_41.4.648.27","doi-asserted-by":"publisher","DOI":"10.1002\/art.23964"},{"key":"2018112909324022000_41.4.648.28","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101659"},{"issue":"Suppl 10","key":"2018112909324022000_41.4.648.29","first-page":"S565","article-title":"Long-term safety and efficacy of 4-weekly certolizumab pegol in combination with methotrexate and as monotherapy in rheumatoid arthritis: 5 year results from an open label extension study","volume":"64","author":"Fleischmann","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2018112909324022000_41.4.648.30","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes082"},{"key":"2018112909324022000_41.4.648.31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study","volume":"73","author":"Landew\u00e9","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2018112909324022000_41.4.648.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2010.01.014"},{"key":"2018112909324022000_41.4.648.33","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2018112909324022000_41.4.648.34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10941.x"},{"key":"2018112909324022000_41.4.648.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062897"},{"key":"2018112909324022000_41.4.648.36","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"2018112909324022000_41.4.648.37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907413"},{"key":"2018112909324022000_41.4.648.38","unstructured":"Hemagglutination inhibition (HAI) test for titrating influenza virus A and B specific antibodies \u2014 Turkey RBCs. Cypress, California, USA: Focus Diagnostics Inc.; 2011."},{"key":"2018112909324022000_41.4.648.39","first-page":"1203","article-title":"Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity","volume":"21","author":"Chalmers","year":"1994","journal-title":"J Rheumatol"},{"key":"2018112909324022000_41.4.648.40","doi-asserted-by":"publisher","DOI":"10.1086\/338043"},{"key":"2018112909324022000_41.4.648.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.12.002"},{"key":"2018112909324022000_41.4.648.42","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(96)70244-0"},{"key":"2018112909324022000_41.4.648.43","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.036434"},{"key":"2018112909324022000_41.4.648.44","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/annrheumdis-2013-203697","article-title":"Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol","volume":"73","author":"van der Heijde","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"Suppl","key":"2018112909324022000_41.4.648.45","first-page":"S730","article-title":"Effect of certolizumab pegol on inflammation of spine and sacroiliac joints in patients with axial spondyloarthritis: 12 week magnetic resonance imaging results of a phase 3 double blind randomized placebo-controlled study","volume":"64","author":"van der Heijde","year":"2012","journal-title":"Arthritis Rheum"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.130945","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T18:37:02Z","timestamp":1543516622000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.130945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,1]]},"references-count":45,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,4,1]]},"published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.3899\/jrheum.130945"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.130945","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,1]]}}}